Essa Pharma Stock Beta
| EPIX Stock | USD 5.77 0.35 5.72% |
ESSA Pharma fundamentals help investors to digest information that contributes to ESSA Pharma's financial success or failures. It also enables traders to predict the movement of ESSA Stock. The fundamental analysis module provides a way to measure ESSA Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ESSA Pharma stock.
ESSA | Beta |
ESSA Pharma Company Beta Analysis
ESSA Pharma's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current ESSA Pharma Beta | 1.84 |
Most of ESSA Pharma's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ESSA Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ESSA Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for ESSA Pharma is extremely important. It helps to project a fair market value of ESSA Stock properly, considering its historical fundamentals such as Beta. Since ESSA Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ESSA Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ESSA Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, ESSA Pharma has a Beta of 1.838. This is 113.72% higher than that of the Biotechnology sector and 32.23% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
ESSA Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ESSA Pharma's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ESSA Pharma could also be used in its relative valuation, which is a method of valuing ESSA Pharma by comparing valuation metrics of similar companies.ESSA Pharma is currently under evaluation in beta category among its peers.
ESSA Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of ESSA Pharma from analyzing ESSA Pharma's financial statements. These drivers represent accounts that assess ESSA Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ESSA Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 14.4M | 28.4M | 154.9M | 80.1M | 136.2M | 61.5K | |
| Enterprise Value | 3.1M | (21.2M) | 98.6M | 23.3M | 102.6M | 60.7K |
ESSA Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ESSA Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ESSA Pharma's managers, analysts, and investors.Environmental | Governance | Social |
ESSA Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in ESSA Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ESSA Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ESSA Pharma's value.| Shares | Parkman Healthcare Partners Llc | 2024-06-30 | 252.1 K | Cibc World Markets Inc. | 2024-06-30 | 80.3 K | D. E. Shaw & Co Lp | 2024-06-30 | 63.5 K | American Century Companies Inc | 2024-06-30 | 46.7 K | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 43.6 K | Royal Bank Of Canada | 2024-06-30 | 36.3 K | Kennedy Capital Management Inc | 2024-06-30 | 34.5 K | Geode Capital Management, Llc | 2024-06-30 | 26.9 K | Citadel Advisors Llc | 2024-06-30 | 25.1 K | Bvf Inc | 2024-06-30 | 8.7 M | Bellevue Group Ag | 2024-06-30 | 7.9 M |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ESSA Pharma will likely underperform.
ESSA Fundamentals
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | 125.66 M | ||||
| Shares Outstanding | 44.37 M | ||||
| Shares Owned By Insiders | 2.26 % | ||||
| Shares Owned By Institutions | 80.08 % | ||||
| Number Of Shares Shorted | 1.12 M | ||||
| Price To Earning | (1.12) X | ||||
| Price To Book | 2.05 X | ||||
| EBITDA | (26.46 M) | ||||
| Net Income | (26.58 M) | ||||
| Cash And Equivalents | 174.6 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 80.33 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 43.43 X | ||||
| Book Value Per Share | 2.90 X | ||||
| Cash Flow From Operations | (19.78 M) | ||||
| Short Ratio | 10.30 X | ||||
| Earnings Per Share | (0.62) X | ||||
| Target Price | 19.8 | ||||
| Number Of Employees | 50 | ||||
| Beta | 1.84 | ||||
| Market Capitalization | 256.01 M | ||||
| Total Asset | 149.12 M | ||||
| Retained Earnings | (179.46 M) | ||||
| Working Capital | 145.3 M | ||||
| Current Asset | 10.02 M | ||||
| Current Liabilities | 3.63 M | ||||
| Net Asset | 149.12 M |
About ESSA Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ESSA Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ESSA Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ESSA Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| AVAV | AeroVironment | |
| ELVN | Enliven Therapeutics | |
| NFLX | Netflix |
Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.